Since the first cases of COVID-19 were reported in the United States, severe ischemic strokes also have been reported in some of these patients, some with large vessel occlusions and case reports of thrombectomy for treatment.
Hypertonic saline given via rapid intermittent bolus therapy was as effective and safe as slow continuous infusion, and was associated with a lower rate of recorrecting treatment and higher efficacy in achieving goal sodium within one hour.
A growing concern about overdiagnosis of attention-deficit/hyperactivity disorder in adolescents and children demonstrates a need for a decisive answer to this concern.
A pooled analysis of three trials of inclisiran in patients with atherosclerotic cardiovascular disease or its risk equivalent showed impressive reductions in LDL cholesterol with subcutaneous injections.
ST-elevation myocardial infarction patients without standard risk factors recorded a higher all-cause mortality rate that was particularly evident in women. Using proper therapy in these patients may attenuate this risk.
The authors applied an automated algorithm to calculate an Agatston coronary artery calcium score from non-ECG-gated planning CT scans in breast cancer patients undergoing radiation therapy. This provided a graded risk calculation that could encourage preventive measures in patients at highest risk of a cardiovascular disease event.
In this study of patients presenting with ST-elevation myocardial infarction and multivessel disease, nonculprit vessel percutaneous coronary intervention (PCI) guided by fractional flow reserve failed to show benefit vs. angiography-guided PCI in terms of clinical events at one year.
A recent study of patients who had undergone a percutaneous coronary intervention and were transitioning from dual antiplatelet therapy to monotherapy showed clopidogrel was superior to aspirin for preventing further major adverse events, including bleeding.
Among patients with newly diagnosed atrial fibrillation age 66-74 years without other CHA2DS2-VASc risk factors for thromboembolism, the older they are in this age range, the more likely they are to experience a stroke.
By adding dapagliflozin to maximally tolerated standard therapy for heart failure with reduced left ventricular ejection fraction, researchers noted the reduction in mortality and recurrent heart failure began within one month of starting this therapy.
